Evidence map›Paper›PMID 15545971›Full record

SynthesisBritish journal of cancer2004

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.

B Martin, M Paesmans, C Mascaux, T Berghmans, P Lothaire, A-P Meert, J-J Lafitte, J-P Sculier

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 12 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 12 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Standardized Uptake Values Derived fromContrast media & molecular imaging · 2018
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Pooled it
  8. Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  9. Pooled it
  10. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Lung cancer chemoprevention with celecoxib in former smokers.Cancer prevention research (Philadelphia, Pa.) · 2011
    Trial
  18. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.European journal of nuclear medicine and molecular imaging · 2010
    Trial
  19. Trial
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

B MartinCritical Care Department and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium. benoit.martin@bordet.be
M Paesmans
C Mascaux
T Berghmans
P Lothaire
A-P Meert
J-J Lafitte
J-P Sculier
Université Libre de Bruxelles · BEFund for Scientific Research · BEHôpital Albert Calmette · FRInstitut Jules Bordet · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among new biological markers that could become useful prognostic factors for lung carcinoma, Ki-67 is a nuclear protein involved in cell proliferation regulation. Some studies have suggested an association between Ki-67 and poor survival in lung cancer patients. In order to clarify this point, we have performed a systematic review of the literature, using the methodology already described by our Group, the European Lung Cancer Working Party. In total, 37 studies, including 3983 patients, were found to be eligible. In total, 49% of the patients were considered as having a tumour positive for the expression of Ki-67 according to the authors cutoff. In all, 29 of the studies dealt with non-small-cell lung carcinoma (NSCLC), one with small-cell carcinoma (SCLC), two with carcinoid tumours and five with any histology. In terms of survival results, Ki-67 was a bad prognosis factor for survival in 15 studies while it was not in 22. As there was no statistical difference in quality scores between the significant and nonsignificant studies evaluable for the meta-analysis, we were allowed to aggregate the survival results. The combined hazard ratio for NSCLC, calculated using a random-effects model was 1.56 (95% CI: 1.30-1.87), showing a worse survival when Ki-67 expression is increased. In conclusion, our meta-analysis shows that the expression of Ki-67 is a factor of poor prognosis for survival in NSCLC.

Indexed as

Biomarkers, TumorHumansKi-67 AntigenLung NeoplasmsPrognosisSurvival AnalysisBiomarkers, TumorKi-67 Antigen

Identifiers

PMID15545971
PMCPMC2409786
OpenAlexW2067757569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.